SCHEMBL10290345

SCHEMBL10290345

Cc1ccc2nc(-c3nc(N4CCC(C)CC4)cnc3N)[nH]c2c1

nearest known ligand 0.51

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ATR Q13535 10/20 0.51
SSTR2 P30874 3/20 0.46
KCNH2 Q12809 3/20 0.46
TRPC3 Q13507 1/20 0.42
NPC1 O15118 3/20 0.42
RAB9A P51151 3/20 0.42
KDM4E B2RXH2 2/20 0.42
ALDH1A1 P00352 2/20 0.42
MAPT P10636 2/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
GAA P10253 1/20 0.42
TP53 P04637 1/20 0.41
PKM P14618 1/20 0.41
HPGD P15428 1/20 0.41
GFER P55789 1/20 0.41
EGFR P00533 1/20 0.40
METAP2 P50579 1/20 0.40
METAP1 P53582 1/20 0.40
CBFB Q13951 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL616156 0.91 ATR (0.52) ATRSSTR2KCNH2NPC1RAB9A
SCHEMBL616833 0.90 ATR (0.49) ATRSSTR2KCNH2NPC1RAB9A
SCHEMBL617267 0.89 ATR (0.64) ATRSSTR2KCNH2
SCHEMBL616805 0.88 ATR (0.48) ATRSSTR2KCNH2NPC1RAB9A
SCHEMBL615028 0.88 ATR (0.51) ATRSSTR2KCNH2NPC1RAB9A
SCHEMBL617596 0.88 ATR (0.48) ATRSSTR2KCNH2NPC1RAB9A
SCHEMBL616623 0.87 ATR (0.53) ATRSSTR2KCNH2MAPTTP53
SCHEMBL614404 0.86 ATR (0.51) ATRSSTR2KCNH2NPC1RAB9A
SCHEMBL614738 0.86 ATR (0.56) ATRKCNH2NPC1RAB9AKDM4E
SCHEMBL10290426 0.86 ATR (0.55) ATRTRPC3ALDH1A1SMN1; SMN2HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120040020-A1 COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-02-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120040020-A1 COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE ATR, CHEK2, CHEK1 ATR 1/4885SSTR2 4346/4885KCNH2 3467/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.